Related Experiment Video
Updated: Jan 20, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Antibodies in hematology by the example of acute lymphatic leukemia]
1AMGEN Research (Munich) GmbH, Staffelseestraße 2, 81477, München, Deutschland. gerhardz@amgen.com.
Antibodies play an important role in the therapy of patients with hematological tumors and have become an established part of this therapy. By using the example of acute lymphoblastic leukemia (ALL), different antibodies with different mechanisms of action are described. The focus of this review is on the description of a bispecific antibody molecule and an immunoconjugate in the relapse of ALL. Although the antibodies have improved the treatment of patients with ALL, it still holds true that the therapy of patients can only be successfully carried out with a strategy that integrates different, mutually complementary schemes. The improvement of therapy can only be achieved through clinical studies with clearly defined protocols.
Antibodies play an important role in the therapy of patients with hematological tumors and have become an established part of this therapy. By using the example of acute lymphoblastic leukemia (ALL), different antibodies with different mechanisms of action are described. The focus of this review is on the description of a bispecific antibody molecule and an immunoconjugate in the relapse of ALL. Although the antibodies have improved the treatment of patients with ALL, it still holds true that the therapy of patients can only be successfully carried out with a strategy that integrates different, mutually complementary schemes. The improvement of therapy can only be achieved through clinical studies with clearly defined protocols.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
06:48In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
09:06Isolation of the Side Population in Myc-induced T-cell Acute Lymphoblastic Leukemia in Zebrafish
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia